New combo aims to shrink stubborn thyroid and salivary tumors
NCT ID NCT03360890
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and docetaxel (chemotherapy)—in people with advanced thyroid or salivary gland cancers that are not responding to standard treatments. The goal is to see if the combo can shrink tumors and help patients live longer. About 46 adults with these rare, hard-to-treat cancers are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.